Bioactivx Raises $3 Mn as Synthetic Wound-Care Product Awaits Singapore Approval

Singapore-based biomaterials start-up Bioactivx raised $3 Mn in a pre-Series A round as it prepares to launch its synthetic wound-care product commercially.

The round was co-led by Singapore venture firm Cocoon Capital and Martin Krupp, whom Bioactivx described in its statement as the managing director of Swiss family office ContInvest. Other new and existing investors also took part in the round. Bioactivx said the financing takes its cumulative funding to $4.9 Mn.

That total is higher than the $4.425 Mn accounted for by the two rounds the company has publicly announced: the latest financing and a $1.425 Mn seed round in November 2025. Bioactivx did not explain the difference in its announcement.

The start-up plans to use the proceeds to expand manufacturing in Singapore, strengthen its commercial and regulatory teams and support post-market clinical trials for Bioactiv Matrix. It is also developing technologies targeting chronic wounds, diabetic ulcers and inflammatory skin conditions.

Bioactiv Matrix is a fully synthetic, bio-inspired skin substitute designed to support tissue regeneration and reduce inflammation without using animal-derived materials. Bioactivx says it does not require cold-chain storage and is designed for application outside sterile operating theatres, which could broaden its use beyond tertiary hospitals.

Research by Bioactivx co-founder Peili Teo predates the company. In 2023, Teo and collaborators from A*STAR and KK Women’s and Children’s Hospital published peer-reviewed work in ACS Materials Au on a 3D-printed dermal scaffold for burn wounds using a synthetic PLGA polymer modified with bioactive components. The study included in vitro and animal work, including a porcine burn model, and reported re-epithelialisation with reduced inflammation compared with Biobrane.

That paper, however, is not published clinical evidence for the commercial Bioactiv Matrix product. Bioactivx has separately said preclinical work on Bioactiv Matrix produced full wound closure within seven days and no inflammation by day 15, while early human trials showed faster recovery than standard care. Those efficacy figures remain company-reported rather than results from a published clinical trial.

The company is also entering a field where synthetic dermal substitutes are already commercial. Australian medical device company PolyNovo’s NovoSorb BTM is a synthetic polyurethane dermal matrix that can be stored at room temperature and is FDA-cleared. PolyNovo sells through its own operations in Singapore, according to company disclosures, and reported unaudited FY26 group revenue of A$150 Mn in July, up 16.1%.

Bioactivx has submitted a full data package for Bioactiv Matrix to Singapore’s Health Sciences Authority (HSA) and is targeting Singapore as one of its first launch markets by the fourth quarter of 2026, subject to approval. It plans to expand into regional markets in 2027.

But the regulatory timetable remains unclear. HSA says the evaluation route for a medical device depends on its risk classification and prior approvals from recognised overseas regulators. For devices requiring full evaluation, published turnaround times run from 160 working days for Class B to 310 for Class D, while priority-review timelines range from 104 to 202 working days. The company did not disclose Bioactiv Matrix’s risk classification or evaluation route in its funding announcement.

HSA accepts medical device dossiers prepared using the ASEAN Common Submission Dossier Template, a standardised format for use across ASEAN regulators and intended to reduce the need to restructure the same technical documentation for each market. That does not make a Singapore approval transferable, but it can reduce filing rework as Bioactivx expands regionally.

The wound-care burden remains substantial. Singapore’s ministry of health said diabetes prevalence among residents aged 18 to 74 was 9.1% in 2023–2024. Diabetic foot ulcers remain a serious complication. Around 1,036 lower limb amputations are performed each year as a consequence, according to research published in Proceedings of Singapore Healthcare.

Bioactivx plans to apply to the US Food and Drug Administration in 2026 and submit under European Union medical device rules in 2027. Its road map also calls for a clinical feasibility study and the start of Series A fundraising this year, followed by a pivotal clinical trial and automated manufacturing in 2027.

The latest financing follows Bioactivx’s November 2025 seed round, which Cocoon Capital also led. That funding was intended to advance regulatory work, broaden the company’s wound-care pipeline and scale its Singapore production facility, which Cocoon said was built to ISO 13485 standards.

Cocoon has continued to reserve capital for follow-on rounds. The firm secured $30 Mn at the first close of its third fund in April 2025 against a $50 Mn target, with about 55% of the fund earmarked for follow-on investments up to Series A.

Bioactivx describes itself as a spin-off from A*STAR and SingHealth. A*STAR independently identifies the company as a spin-off from its Institute of Materials Research and Engineering and says it went through its Open Mike, Essentials and Elevate venture-building programmes before drawing investor interest at a 2023 innovation competition in Suzhou.

Teo is Bioactivx’s co-founder and director of technology as well as a principal scientist at IMRE. Yew Lok Woo, a consultant orthopaedic and trauma surgeon at Singapore General Hospital, is co-founder and clinical lead. Mickey Cheong is co-founder and chief operating officer. He also leads AI agent workforce product strategy at Sendbird, a business messaging infrastructure company.

Cocoon’s portfolio page does not identify a chief executive for Bioactivx.